Glaxosmithkline Plc (GSK)
$36.18 0.39 (1.07%)
19:00 EDT GSK Stock Quote Delayed 30 Minutes
Previous Close -
Market Cap 89.72B
PE Ratio 86.97
Volume (Avg. Vol.) 3.49M
Day's Range 36.08 - 36.77
52-Week Range 31.43 - 48.25
Dividend & Yield 2.14 (5.91%)
GSK Stock Predictions, Articles, and Glaxosmithkline Plc News
- From InvestorPlace
- From the Web
GlaxoSmithKline and Sanofi stock are rallying in early trading on Friday thanks to news they would supply the EU 300 million vaccine doses.
By Thomas Niel
Whether or not we get an 'October Surprise' from President Donald Trump, these coronavirus vaccine stocks look hot now. AstraZeneca (NYSE:AZN) CureVac (NASDAQ:CVAC) GlaxoSmithKline (NYSE:GSK) Inovio (NASDAQ:INO) Johnson & Johnson (NYSE:JNJ) Moderna (NASDAQ:MRNA) Novavax (NASDAQ:NVAX)
Although broader markets may continue to be volatilie in the rest of the year, these five hot stocks to buy should be on your shopping list.
As the market continues to deal with the pandemic, these five cheap drug stocks have solid dividend yields of 4% and almost 37% upside.
Friday's big stock charts feature pharmaceutical-market names that recently posted terrific earnings data.
A number of S&P 500 companies have already increased their 2020 dividends by 10% or more. Here are 10 stocks to buy among this group.
Amarin is targeting a huge market, and its main drug -- Vascepa -- is likely to be expanded in its coverage. Here’s a look at what’s ahead for the stock.
Turning Point Brands, Cronos Group and Altria are just some of the stocks to buy or sell here at a pivotal time for vaporizers.
With international dividend stocks, valuations are generally better and yields are bigger. Here are five stocks that stand out.
These ten stocks aren't exactly household names, but they each deserve a spot in a list of small-cap stocks to buy now for traders that can deal with the risk for the potential of high reward.
Think all blue-chip stocks are safe buys at any time? Think again. These companies may be about to stumble, if they haven't already.
These three biopharma stocks to buy should help investors maintain strength amid any potential chaos in 2019.
GlaxoSmithKline (GSK) stock is up today on news of a new joint venture with Pfizer (PFE) for a consumer healthcare business.
The stock charts of ROST, D and MS are shaping up as the top trading prospects as December's action gets going.
Tesaro stock was flying high on Monday with news that GlaxoSmithKline (GSK) is planning to acquire it in a deal worth $5.10 billion.
If you're looking for the best dividend stocks with high yields and solid growth prospects, don't limit yourself -- look overseas.
These seven healthcare stocks are coming to life Monday. Here's how to play these companies without getting burnt.
GlaxoSmithKline pays shareholders a solid dividend yet the company is not just for income investors. In the next few years, growth in the consumer unit will lead to strong cash flow, raising the chances of dividend hikes for GSK stock.
Small-cap stocks have been on a tear of late. Take the hint, and start your search with these seven top prospects.
From Seeking Alpha
The European Medicines Agency's advisory group CHMP has adopted a positive opinion recommending approval for Viiv Healthcare's Vocabria (cabotegravir injection and tablets) in combination with Rekambys (rilpivirine injection) and Edurant (rilpivirine tablets), for the treatment of HIV-1 infection who are virologically stable and suppressed (HIV-1 RNA less than 50 copies/mL) and not resistant to either drug.ViiV Healthcare is the HIV-focused joint venture between GlaxoSmithKline (NYSE:GSK), Pfizer (NYSE:PFE) and Shionogi (OTCPK:SGIOF)
From Talk Markets
Navellier RatingsPowered by Portfolio Grader